Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Forero-Torres

Showing results (51-60 of 91) with videos related to

Pageof 10
Sort By:
Cancer Medicine|January 10, 2014
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancerAndres Forero-Torres, Jeffrey R Infante, David Waterhouse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2012
Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphomaAndres Forero-Torres, Sven de Vos, Brad L Pohlman, et al.
Cancer|January 10, 2019
A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinomaSumanta K Pal, Andres Forero-Torres, John A Thompson, et al.
Blood|April 29, 2018
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphomaAnn S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
British Journal of Haematology|February 13, 2020
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphomaAnn S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
Haematologica|June 24, 2021
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 studyAndrew M Evens, Joseph M Connors, Anas Younes, et al.
Breast Cancer Research and Treatment|October 25, 2017
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor studyLuc Y Dirix, Istvan Takacs, Guy Jerusalem, et al.
NPJ Breast Cancer|May 21, 2021
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter studyLinda T Vahdat, Peter Schmid, Andres Forero-Torres, et al.
Leukemia & Lymphoma|April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphomaKristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
Leukemia & Lymphoma|October 3, 2018
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER studyJeff P Sharman, Andres Forero-Torres, Luciano J Costa, et al.
Pageof 10

Showing results (51-60 of 91) with videos related to

Sort By:
Pageof 10
Cancer Medicine|January 10, 2014
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancerAndres Forero-Torres, Jeffrey R Infante, David Waterhouse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2012
Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphomaAndres Forero-Torres, Sven de Vos, Brad L Pohlman, et al.
Cancer|January 10, 2019
A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinomaSumanta K Pal, Andres Forero-Torres, John A Thompson, et al.
Blood|April 29, 2018
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphomaAnn S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
British Journal of Haematology|February 13, 2020
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphomaAnn S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
Haematologica|June 24, 2021
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 studyAndrew M Evens, Joseph M Connors, Anas Younes, et al.
Breast Cancer Research and Treatment|October 25, 2017
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor studyLuc Y Dirix, Istvan Takacs, Guy Jerusalem, et al.
NPJ Breast Cancer|May 21, 2021
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter studyLinda T Vahdat, Peter Schmid, Andres Forero-Torres, et al.
Leukemia & Lymphoma|April 11, 2014
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphomaKristen N Ganjoo, Sven de Vos, Brad L Pohlman, et al.
Leukemia & Lymphoma|October 3, 2018
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER studyJeff P Sharman, Andres Forero-Torres, Luciano J Costa, et al.
Pageof 10